BioCentury
ARTICLE | Finance

Stars align for rare AMD

Why investors are backing Gemini to apply precision medicine in dry AMD

October 20, 2017 8:59 PM UTC

Investors have backed Gemini Therapeutics Inc. with a $42.5 million series A round so the company can use the precision medicine approach that is common to cancer and rare diseases to target mutations in the complement system in dry age-related macular degeneration.

On Oct. 17, Gemini emerged from stealth to announce the A round, which was co-led by Atlas Venture, Lightstone Ventures and OrbiMed Advisors. The three firms also participated in an undisclosed seed financing for the company in 2016. ...